AWS Launches the AI Shortcut Pharma Has Been Waiting For

Amazon Bio Discovery gives pharma researchers AI-powered drug candidate generation without coding skills

15 Apr 2026

Amazon Web Services has launched Amazon Bio Discovery, a platform giving pharmaceutical researchers direct access to more than 40 biological AI models for early-stage drug development, the company announced on 14 April.

The tool addresses a persistent constraint in the industry: a shortage of computational biologists able to translate laboratory objectives into machine-learning workflows. A conversational AI agent guides scientists through model selection, experiment design, and the evaluation of candidate molecules. Promising compounds can then be routed to integrated laboratory partners for physical synthesis, with results fed back into the system to inform subsequent design cycles.

In a collaboration with Memorial Sloan Kettering Cancer Center, the platform generated nearly 300,000 novel antibody molecules, filtering the pool to 100,000 candidates for laboratory testing, a process the company said would normally take more than a year but was compressed into weeks. Bayer, the Broad Institute, and Voyager Therapeutics are among early adopters. AWS said 19 of the top 20 global pharmaceutical companies already use its cloud infrastructure for research workloads.

At the same Life Sciences Symposium, AWS also unveiled a separate platform developed with Boston Consulting Group and Merck aimed at improving clinical trial site selection, one of the more consequential delays between drug discovery and patient access. Amazon Bio Discovery operates on a subscription model with a free five-experiment tier.

Jefferies analyst Tycho Peterson said faster, more productive drug development programmes were likely to drive higher overall investment in scientific tools rather than displace it.

The platform enters a market where several technology groups, including Google and Microsoft, have made significant commitments to biological AI. How quickly outputs from such systems translate into approved therapies, and how regulators treat AI-generated molecular candidates, remains an open question for the industry.